logo
  

Institutional Financial Markets Names Lester Brafman CEO

Institutional Financial Markets Inc. (IFMI) announced that it has appointed Lester Brafman as Chief Executive Officer, effective immediately. Brafman, who has served as President of IFMI since June 2013, succeeds Daniel Cohen.

Cohen will transition from Chief Executive Officer and Chief Investment Officer of IFMI to President and Chief Executive of IFMI's European operations, where he will continue to focus on growing the Company's European capital markets and asset management operations.

Until the closing of IFMI's announced transaction with Mead Park Capital Partners LLC, and Cohen Bros. Financial, LLC, Cohen will continue to serve as Chairman of IFMI.

During an 11-year tenure at Goldman Sachs, Brafman served as Chief Operating Officer of Credit and Mortgage Trading, and as Head of High Yield and Distressed Trading. Prior to joining Goldman Sachs in 2001, Brafman, 51, spent over six years at Credit Suisse First Boston, holding numerous roles of increasing responsibility, most recently as Head of High Yield Trading, and previously Head of Emerging Market and Sovereign Trading. He also spent several years at Wasserstein Perella & Co. and Lehman Brothers, respectively.

The company expects to close its announced transaction with Mead Park Capital Partners LLC and Cohen Bros, as previously disclosed. Financial, LLC immediately following IFMI's 2013 Annual Meeting of Stockholders, which is scheduled to take place on September 24, 2013. At that time, Jack DiMaio, Chief Executive Officer and founder of Mead Park, will be named Chairman, and Cohen will be named Vice Chairman of the Board of IFMI.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT